Compare BABA & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BABA | NVS |
|---|---|---|
| Founded | 1999 | 1895 |
| Country | Hong Kong | Switzerland |
| Employees | 126661 | 75267 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.7B | 310.4B |
| IPO Year | N/A | N/A |
| Metric | BABA | NVS |
|---|---|---|
| Price | $136.11 | $155.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 4 |
| Target Price | ★ $189.42 | $118.00 |
| AVG Volume (30 Days) | ★ 8.2M | 2.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 0.77% | ★ 1.92% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.96 | $2.56 |
| Revenue Next Year | $11.04 | $4.91 |
| P/E Ratio | ★ $21.20 | $23.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $95.90 | $97.72 |
| 52 Week High | $192.67 | $170.46 |
| Indicator | BABA | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 33.79 | 42.95 |
| Support Level | $116.81 | $113.19 |
| Resistance Level | $158.69 | $158.80 |
| Average True Range (ATR) | 3.23 | 2.44 |
| MACD | -1.01 | -1.63 |
| Stochastic Oscillator | 27.23 | 4.39 |
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China retail e-commerce platform is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China wholesale e-commerce, international retail and wholesale e-commerce, local consumer services, travel services, cloud computing, digital media and entertainment, Cainiao logistics services, and other businesses.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.